Ultragenyx Pharmaceutical (RARE) Return on Capital Employed (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has 13 years of Return on Capital Employed data on file, last reported at 51.52% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 549.0% year-over-year to 51.52% in Q1 2026; TTM through Mar 2026 was 51.52%, a 549.0% decrease from a year earlier, with the FY2025 full-year figure at 47.2%, down 71.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 51.52%, up from 54.75% in the prior quarter.
• Over the last five years, Return on Capital Employed for RARE reached as high as 32.02% in Q1 2022 and fell as low as 60.99% in Q2 2023.
• Historically, Return on Capital Employed has averaged 49.52% across 5 years, with a median of 49.73% in 2025.
• Across the five-year window, Return on Capital Employed plunged 2145 bps in 2023 and soared 1667 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 49.13% in 2022, then declined by 7 bps to 52.48% in 2023, then gained by 13 bps to 45.55% in 2024, then retreated by 20 bps to 54.75% in 2025, then increased by 6 bps to 51.52% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 51.52% in Q1 2026, 54.75% in Q4 2025, and 59.9% in Q3 2025.